JPRN-UMIN000004383已完成未知
Efficacy and safety of a four-week treatment with budesonide/formoterol in patients with cough variant asthma: Open-label, randomized and parallel-group study compared with budesonide. - Controlled study to compare the effect of budesonide/formoterol and budesonide in cough variant asthma.
Kyoto University Graduate School of Medicine0 个研究点目标入组 80 人开始时间: 2010年10月14日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients with hypersensitivity to Budesonide/formoterol. 2. Patients with other respiratory diseases. 3. Patients who take inhaled corticosteroids in the last 4 weeks 4. Patients who take long acting beta agonists in the last 5 days 5. Patients who take antiallergy agents and inhaled anticholinergic in the last 2 weeks 6. Patients who are given systemic corticosteroids in the last 30 days 7. Current smoker or ex-smoker of > 10 pack-years 8. Pregnancy or lactation 9. Patients who are considered inappropriate by physicians in charge
研究者
相似试验
进行中（未招募）
不适用
EVALUATION OF THE EFFECT OF 4 WEEKS TREATMENT WITH CHF 4226 pMDI 2µg DOSE GIVEN ONCE DAILY IN THE EVENING ON 24-HOUR TROUGH FEV1 IN ADULT AND ADOLESCENT PATIENTS AGED 15 YEARS OR OVER WITH MODERATE OR SEVERE PERSISTANT ASTHMA.A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PARALLEL GROUP, PLACEBO AND ACTIVE (FORMOTEROL 12µg B.I.D.) CONTROLLED, EFFICACY, SAFETY AND TOLERABILITY STUDY.Persistent asthmaMedDRA version: 8.1Level: PTClassification code 10003553Term: AsthmaEUCTR2006-005689-38-HUChiesi Farmaceutici S.p.A.240
进行中（未招募）
1 期
EVALUATION OF THE EFFECT OF 4 WEEKS TREATMENT WITH CHF 4226 pMDI 2µg DOSE GIVEN ONCE DAILY IN THE EVENING ON 24-HOUR TROUGH FEV1 IN ADULT AND ADOLESCENT PATIENTS AGED 15 YEARS OR OVER WITH MODERATE OR SEVERE PERSISTANT ASTHMA. A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PARALLEL GROUP, PLACEBO AND ACTIVE (FORMOTEROL 12µg B.I.D.) CONTROLLED, EFFICACY, SAFETY AND TOLERABILITY STUDY.Persistent asthmaMedDRA version: 14.0 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2006-005689-38-GBChiesi Farmaceutici S.p.A.240
进行中（未招募）
1 期
EVALUATION OF THE EFFECT OF 4 WEEKS TREATMENT WITH CHF 4226 pMDI 2µg DOSE GIVEN ONCE DAILY IN THE EVENING ON 24-HOUR TROUGH FEV1 IN ADULT AND ADOLESCENT PATIENTS AGED 15 YEARS OR OVER WITH MODERATE OR SEVERE PERSISTANT ASTHMA.A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PARALLEL GROUP, PLACEBO AND ACTIVE (FORMOTEROL 12µg B.I.D.) CONTROLLED, EFFICACY, SAFETY AND TOLERABILITY STUDY.Persistent asthmaMedDRA version: 8.1Level: PTClassification code 10003553Term: AsthmaEUCTR2006-005689-38-BGChiesi Farmaceutici S.p.A.240
进行中（未招募）
1 期
Study of the efficacy and safety of Lcr Regenerans®_GynoCans.EUCTR2013-002480-26-PLBIOSE234
进行中（未招募）
1 期
Study of the efficacy and safety of treatment administered intravaginallyin the treatment of bacterial vaginosis.MedDRA version: 19.0Level: LLTClassification code 10046960Term: Vaginosis bacterialSystem Organ Class: 100000004862Bacterial vaginosisEUCTR2015-004563-37-PLaboratoires IPRAD PHARMA530